nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2010 | Original Article

Visual assessment of [¹¹C]PIB PET in patients with cognitive impairment

verfasst von: Timo Suotunen, Jussi Hirvonen, Pirjo Immonen-Räihä, Sargo Aalto, Irina Lisinen, Eveliina Arponen, Mika Teräs, Kari Koski, Raimo Sulkava, Marko Seppänen, Juha O. Rinne

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the visual assessment of positron emission tomography images of N-[methyl-11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB) in a patient population with mild to moderate memory impairment or dementia.

Methods

We compared the visual ratings of two readers using kappa statistics and correlated the results of visual and quantitative region of interest (ROI) analyses. The one reader had good experience in evaluating PIB images and the other had little previous experience. The sensitivity and specificity of the visual assessment was determined using quantitative data from 18 healthy controls previously examined: [11C]PIB uptake was considered as abnormal if it was more than 2 SD above the mean of the healthy subjects.

Results

The evaluation of visual classification as “normal” or “abnormal” showed good interobserver agreement (κ = 0.90). There was a clear correlation between visual and quantitative analysis (r = 0.47–0.79, p < 0.001). The most difficult visually assessed brain area was the putamen (κ = 0.11; correlation with quantitative analysis: reader A r = 0.22; reader B r = 0.60).

Conclusion

Our study shows that visual evaluation of [¹¹C]PIB images conforms with quantitative analyses also in a clinical patient population supporting the feasibility of visual evaluation in clinical settings.

Ritchie K, Lovestone S. The dementias. Lancet 2002;360:1759–66.CrossRefPubMed

Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431–4.CrossRefPubMed

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19.CrossRefPubMed

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575–80.CrossRefPubMed

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718–25.CrossRefPubMed

Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007;68:501–8.CrossRefPubMed

Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229–34.CrossRefPubMed

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68:1603–6.CrossRefPubMed

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456–65.CrossRefPubMed

10.

Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med 2007;48:547–52.CrossRefPubMed

11.

Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834–40.CrossRefPubMed

12.

Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959–72.PubMed

13.

Morris J, Mohs R, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer’s disease (CERAD) clinical and neuropsychological assessment of Alzheimer’s disease. Psychopharmacol Bull 1988;24:641–52.PubMed

14.

Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein H, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967–72.CrossRefPubMed

15.

Lowe V, Kemp B, Jack CR Jr, Senjem M, Weigand S, Shiung M, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009;50:878–86.CrossRefPubMed

16.

de Leon M, DeSanti S, Zinkowski R, Mehta P, Pratico D, Segal S, et al. MRI and CSF studies in the early diagnosis of Alzheimer’s disease. J Intern Med 2004;256:205–23.CrossRefPubMed

17.

Jack CJ, Petersen R, Xu Y, O’Brien P, Waring S, Tangalos E, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Ann Neurol 1998;43:303–10.CrossRefPubMed

18.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–34.CrossRefPubMed

19.

Fagan A, Mintun M, Mach R, Lee S, Dence C, Shah A, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512–9.CrossRefPubMed

20.

Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka S, Jauhianen A, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:378–83.CrossRefPubMed

21.

Swartz R, Black S, Sela G, Bronskill M. Cognitive impairment in dementia: correlations with atrophy and cerebrovascular disease quantified by magnetic resonance imaging. Brain Cogn 2002;49:228–32.PubMed

22.

Fein G, Di Sclafani V, Tanabe J, Cardenas V, Weiner M, Jagust W, et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 2000;55:1626–35.PubMed

23.

Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174–84.CrossRefPubMed

24.

Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer’s disease. Brain 2008;131:1845–53.CrossRefPubMed

25.

Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Mononen H, et al. Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 2008;65:540–4.CrossRefPubMed

26.

Oakes TR, Christian BT, Roberts AD, Pyzalski RW, Holden JE, Brown T, et al. Multi-scanner PET 2D/3D comparison with cerebral FDG. IEEE Nucl Sci Symp Conf Rec 2001;3:1272–6.

27.

Baghaei H, Mawlawi O, Yu W, Hongdi L, Ramirez R, Soonseok K, et al. A comparison of five whole-body PET scanners by scanning Hoffman brain phantom. IEEE Nucl Sci Symp Conf Rec 2006;4:1973–6.CrossRef

28.

van Velden FHP, Kloet RW, de Jong HWAM, Lammertsma AA, Boellaard R. Quantitative experimental comparison of HRRT versus HR+PET brain studies. IEEE Nucl Sci Symp Conf Rec 2006;5:3097–9.CrossRef

29.

Yaqub M, Tolboom N, Boellaard R, van Berckel B, van Tilburg E, Luurtsema G, et al. Simplified parametric methods for [11C]PIB studies. Neuroimage 2008;42:76–86.CrossRefPubMed

30.

Aalto S, Scheinin N, Kemppainen N, Någren K, Kailajärvi M, Leinonen M, et al. Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data. Eur J Nucl Med Mol Imaging 2009;36:1651–60.CrossRefPubMed

31.

McNamee R, Yee S, Price J, Klunk W, Rosario B, Weissfeld L, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009;50:348–55.CrossRefPubMed

Titel: Visual assessment of [11C]PIB PET in patients with cognitive impairment
verfasst von: Timo Suotunen
Jussi Hirvonen
Pirjo Immonen-Räihä
Sargo Aalto
Irina Lisinen
Eveliina Arponen
Mika Teräs
Kari Koski
Raimo Sulkava
Marko Seppänen
Juha O. Rinne
Publikationsdatum: 01.06.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1382-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study

Risk stratification of solitary pulmonary nodules by means of PET using 18F-fluorodeoxyglucose and SUV quantification

Skin metastasis of follicular thyroid carcinoma

18F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis

Measurement of coronary flow reserve by noninvasive cardiac imaging

18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging